Unlearn has unveiled a web-based application aimed at revolutionising the efficiency of clinical trial planning.

TrialPioneer is now available for free to pharmaceutical and biotech enterprises, offering insights into how various trial design choices can influence sample size needs, statistical power, and enrolment timelines.

In the initial stage, the tool is equipped to provide insights into seven major disease areas, namely Alzheimer’s, ALS, Crohn’s, Frontotemporal dementia, Huntington’s, Parkinson’s, and ischemic stroke.

TrialPioneer is tailored to enhance the workflow of medical directors, clinicians, and statisticians.

It utilises comprehensive datasets of Unlearn from past patient populations to allow users to assess the impact of trial design decisions on essential metrics such as sample size and power.

Additionally, the application shows how TwinRCTs of Unlearn can optimise these metrics by using digital twins to conduct more efficient clinical trials.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

TrialPioneer will assist in raising awareness of trial designs that use AI in compliance with regulations.

The European Medicines Agency qualified the technology that powers TwinRCTs for use as the primary analysis in Phase II and Phase III clinical trials with continuous outcomes. The US Food and Drug Administration has agreed that the methodology does not deviate from current guidelines.

The escalating costs associated with new medication development, which can exceed $1bn and take up to 14 years, underscore the importance of efficient trial design.

Clinical teams are tasked with evaluating numerous variables and conducting analyses to determine their potential effects on a trial’s sample size, power, and success probability.

TrialPioneer streamlines this process, enabling teams to rapidly explore various trial designs, thus facilitating more informed decision-making and potentially reducing the time and cost of drug development.

Unlearn founder and CEO Charles Fisher said: “Everyone involved in clinical research knows that trials are frustratingly slow from the get-go.

“With TrialPioneer, we’re offering a free, powerful, and easy-to-use tool that enables anyone from any background to explore trial planning in a simple way, even with innovative trial designs that leverage tools like AI. We hope people will use it to make faster, more informed decisions to accelerate their research programmes.”

The latest development comes after Unlearn secured $50m in a Series C funding round led by Altimeter Capital, for optimising clinical research with digital twin technology.